# Intravenous Immunoglobulin for Acute Intracranial Hemorrhage

> **NCT02782897** · PHASE2 · UNKNOWN · sponsor: **Wei Wang** · enrollment: 60 (estimated)

## Conditions studied

- Intracranial Hemorrhage, Hypertensive

## Interventions

- **DRUG:** Immunoglobulin Therapy
- **OTHER:** Standard management

## Key facts

- **NCT ID:** NCT02782897
- **Lead sponsor:** Wei Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782897, "Intravenous Immunoglobulin for Acute Intracranial Hemorrhage". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02782897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*